Guy Martin

News Editor and Reporter at The Pharma Letter

Featured in: Favicon

thepharmaletter.com Favicon

getsurrey.co.uk Favicon

mondaq.com Favicon

beamstart.com Favicon

ejves.com

tasteoffrancemag.com Favicon

forbesuruguay.com

Articles

Achieve adds vapers to smokers in targeting multi-billion dollar market

5 days ago | thepharmaletter.com | Guy Martin

Armed with an asset that could be an improvement on Pfizer’s (NYSE: PFE) blockbuster smoking cessation drug Chantix/Champix (varenicline), Achieve Life Sciences (Nasdaq: ACHV) has confidence in its prospects of addressing the global smoking health and nicotine addiction epidemic.
Boehringer taking role as educator in CRM space seriously

2 weeks ago | thepharmaletter.com | Guy Martin

Last month, the Future Health Report was presented at the World Health Assembly in Geneva, Switzerland. The report states that it is time for policymakers to adopt more holistic and interconnected approaches—from funding to clinical guidelines and care models—to tackle the non-communicable diseases (NCDs) challenge.
With tislelizumab, BeiGene brings immunotherapy to more patients in Europe

Jan 16, 2025 | thepharmaletter.com | Guy Martin

This executive interview, sponsored by BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene. Almost every week brings news on the progress of tislelizumab, BeiGene’s (Nasdaq: BGNE) uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1.
ASH 2024: Hematologists ready for big showcase

Dec 1, 2024 | thepharmaletter.com | Guy Martin

Privacy Policy When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies.
Pentixapharm: the radiopharmaceutical company with a head start on its rivals

Sep 5, 2024 | thepharmaletter.com | Guy Martin

Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. As a result of this growth, one little known company, Pentixapharm, is expected soon to be making news on both sides of the Atlantic.
Ambition, agility and doing what’s best for patients: the components of Accord’s incredible success

Aug 14, 2024 | thepharmaletter.com | Guy Martin

Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. Furthermore, finding a more agile drugmaker than Accord would be difficult—a factor that has been key to the company’s rapid rise and explains the extent of Accord’s ambitions for further growth.
Vogue cierra la Semana de la Moda de París con un gran desfile en la Place Vendôme

Jun 25, 2024 | forbesuruguay.com | Guy Martin

Conde Nast y Anna Wintour, redactora jefe de Vogue, clausuraron la semana de la moda masculina primavera-verano 2025 de París con la mayor explosión imaginable, ocupando la totalidad de la plaza Vendôme de la ciudad, con un backstage de 38.000 metros cuadrados, una orquesta completa y un divertido y exagerado homenaje a un siglo de moda y deporte parisinos en forma de desfile en la noche del 23 de junio.
Growing admirers for Sibylla’s tech targeting ‘paradigm shift in drug design’

Jun 17, 2024 | thepharmaletter.com | Guy Martin

It is not every day that an Italian biotech company raises 23 million euros ($24.7 million) in a Series A financing. When they funded the round back in 2022, the international syndicate of life science investors clearly felt that Sibylla Biotech was onto something exciting with its pharmacological protein inactivation by folding intermediates targeting (PPI-FIT) technology.
GAIA’s AI-driven products based on proven, powerful benefits for physicians and patients

Jun 4, 2024 | thepharmaletter.com | Guy Martin

Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. Instead, the company - which is focused on the development of evidence-based, safe and accessible AI-powered DTx products that help patients restore and maintain their mental and physical health - has played a major role in driving the emerging field.
Confident Abivax aims to disrupt IBD landscape

May 13, 2024 | thepharmaletter.com | Guy Martin

Marc de Garidel, chief executive of French clinical-stage biotech Abivax (Nasdaq: ABVX), has good reason for his belief in the company’s pioneering lead asset, obefazimod. The highly differentiated oral drug candidate, a small molecule, with a novel mechanism of action based on the expression of a single microRNA, miR-124, to stabilize the immune response, has generated impressive data in several preclinical and clinical studies.